These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 20814720)

  • 1. Nanotechnology-based cancer therapeutics--promise and challenge--lessons learned through the NCI Alliance for Nanotechnology in Cancer.
    Farrell D; Ptak K; Panaro NJ; Grodzinski P
    Pharm Res; 2011 Feb; 28(2):273-8. PubMed ID: 20814720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance.
    Zamboni WC; Torchilin V; Patri AK; Hrkach J; Stern S; Lee R; Nel A; Panaro NJ; Grodzinski P
    Clin Cancer Res; 2012 Jun; 18(12):3229-41. PubMed ID: 22669131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances from the National Cancer Institute Alliance for Nanotechnology in Cancer.
    Farrell D; Alper J; Ptak K; Panaro NJ; Grodzinski P; Barker AD
    ACS Nano; 2010 Feb; 4(2):589-94. PubMed ID: 20175564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NCI Alliance for Nanotechnology in Cancer: achievement and path forward.
    Ptak K; Farrell D; Panaro NJ; Grodzinski P; Barker AD
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(5):450-60. PubMed ID: 20552623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National Cancer Institute Alliance for nanotechnology in cancer-Catalyzing research and translation toward novel cancer diagnostics and therapeutics.
    Hartshorn CM; Russell LM; Grodzinski P
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Nov; 11(6):e1570. PubMed ID: 31257722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations.
    Zhang DY; Dmello C; Chen L; Arrieta VA; Gonzalez-Buendia E; Kane JR; Magnusson LP; Baran A; James CD; Horbinski C; Carpentier A; Desseaux C; Canney M; Muzzio M; Stupp R; Sonabend AM
    Clin Cancer Res; 2020 Jan; 26(2):477-486. PubMed ID: 31831565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highlights of recent developments and trends in cancer nanotechnology research--view from NCI Alliance for Nanotechnology in Cancer.
    Hull LC; Farrell D; Grodzinski P
    Biotechnol Adv; 2014; 32(4):666-78. PubMed ID: 23948249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanotechnology platforms; an innovative approach to brain tumor therapy.
    Nair BG; Varghese SH; Nair R; Yoshida Y; Maekawa T; Kumar DS
    Med Chem; 2011 Sep; 7(5):488-503. PubMed ID: 21801148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
    Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
    Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy.
    Piktel E; Niemirowicz K; Wątek M; Wollny T; Deptuła P; Bucki R
    J Nanobiotechnology; 2016 May; 14(1):39. PubMed ID: 27229857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating Nanotechnology into Cancer Care.
    Grodzinski P; Kircher M; Goldberg M; Gabizon A
    ACS Nano; 2019 Jul; 13(7):7370-7376. PubMed ID: 31240914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoscale drug delivery for targeted chemotherapy.
    Xin Y; Huang Q; Tang JQ; Hou XY; Zhang P; Zhang LZ; Jiang G
    Cancer Lett; 2016 Aug; 379(1):24-31. PubMed ID: 27235607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles.
    Niu Y; Zhu J; Li Y; Shi H; Gong Y; Li R; Huo Q; Ma T; Liu Y
    J Control Release; 2018 May; 277():35-47. PubMed ID: 29545106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The upcoming field of theranostic nanomedicine: an overview.
    Prabhu P; Patravale V
    J Biomed Nanotechnol; 2012 Dec; 8(6):859-82. PubMed ID: 23029995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicine: a new frontier in cancer therapeutics.
    Lee PY; Wong KK
    Curr Drug Deliv; 2011 May; 8(3):245-53. PubMed ID: 21291378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized Cancer Nanomedicine: Overcoming Biological Barriers for Intracellular Delivery of Biopharmaceuticals.
    López-Estévez AM; Lapuhs P; Pineiro-Alonso L; Alonso MJ
    Adv Mater; 2024 Apr; 36(14):e2309355. PubMed ID: 38104275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study.
    Eifler AC; Thaxton CS
    Methods Mol Biol; 2011; 726():325-38. PubMed ID: 21424459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of Drug Delivery Technology and Nanomedicine by Using Gold Nanoparticles].
    Ozeki T; Tagami T
    Yakugaku Zasshi; 2021; 141(3):323-326. PubMed ID: 33642498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on current and potential nanoparticle cancer therapies.
    Rink JS; Plebanek MP; Tripathy S; Thaxton CS
    Curr Opin Oncol; 2013 Nov; 25(6):646-51. PubMed ID: 24097107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.